Lymphoma Clinical Trials in Philadelphia

Showing 441-460 of 599 trials

Cardiotoxicity of Radiation Therapy (CTRT)

NCT02769299

The overall objective of this proposal is to determine the utility of sensitive imaging and biomarker measures in detecting subclinical cardiotoxicity across a spectrum of radiation doses to the heart. We will focus specifically on patients receiving photon or proton chest radiotherapy. Our broad working hypothesis is that RT induces early, subclinical CV injury, as evidenced by cardiomyocyte inflammation and necrosis, and worsening CV function.

Breast CancerLung CancerMediastinal Lymphomas

Abramson Cancer Center at Penn Medicine147 participantsStarted Jun 2015

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 1< 1 mile

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

NCT00073749

To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).

Lymphoma, B-Cell

Pfizer79 participantsStarted Aug 2003

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +19 more locations

Cardiotoxicity of Radiation Therapy (CTRT)

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Lymphoma Trials in Other Cities

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

A Study of Enzastaurin in Participants With Follicular Lymphoma

Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma

Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Evaluation of ClearLLab Leukemia and Lymphoma Panels

Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma

Other Conditions in Philadelphia